Nuvation Bio’s Taletrectinib NDA for ROS1+ NSCLC Receives FDA Priority Review
US-based Nuvation Bio Inc. (NYSE: NUVB) has announced that the New Drug Application (NDA) for...
Shanghai Henlius Biotech Initiates Patient Dosing in Global Phase III ELAINE-3 Study for Lasofoxifene
Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company based in China, has announced...
RaysightMed’s AngioQFA 100 Receives NMPA Approval for Coronary Artery Function Measurement
China-based RaysightMed Co., Ltd has announced that it has received marketing approval from the National...
uBriGene Secures RMB 200 Million in Pre-Series D Financing to Expand ATMPs CDMO Services
China-based uBriGene, a contract development and manufacturing organization (CDMO) focused on advanced therapy medicinal products...
WuXi AppTec to Divest WuXi Advanced Therapies and Oxford Genetics to Altaris LLC
China-based Contract Development and Manufacturing Organization (CDMO) WuXi AppTec Co., Ltd (SHA: 603259) has announced...
Basecare Medical and SolarCare Form Alliance to Advance AI in IVF Services
Suzhou Basecare Medical Co., Ltd (HKG: 2170), a leading China-based in vitro fertilization (IVF) specialist,...
Alphamab Oncology’s JSKN033 Gets Green Light for Phase I/II Study from China’s CDE
China-based Alphamab Oncology (HKG: 9966) has announced that it has received approval from the Center...
CSPC Pharmaceutical’s SYH2062 Receives NMPA Clearance for Hypertension Treatment
China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has announced that it has received clinical...
Keymed Biosciences’ Kangyueda Approved for CRSwNP Treatment in China
China-based Keymed Biosciences Inc., (HKG: 2162) has announced that it has received another indication approval...
Sichuan Biokin’s GNC-038 Tetra-Specific Antibody Clears for Clinical Trials in Autoimmune Diseases
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced that it...
Changchun High & New Technology Industries Receives FDA Approval for Menopausal VMS Drug Trial
China-based Changchun High & New Technology Industries (Group) Inc., (SHE: 000661) has received the green...
AstraZeneca’s Tagrisso Secures EU Approval for EGFR-Mutated Locally Advanced NSCLC
UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) has announced that the European Commission (EU) has...
Ikena Oncology and Inmagene Biopharmaceuticals to Merge into ImageneBio, Listed on Nasdaq as ‘IMA’
US-based Ikena Oncology, Inc. (NASDAQ: IKNA) and Sino-US biotech Inmagene Biopharmaceuticals have announced their merger...
Sanofi and SK bioscience Broaden Partnership to Develop Next-Gen Pneumococcal Vaccines
French pharmaceutical major Sanofi (NASDAQ: SNY) and South Korea-based SK bioscience (KRX: 302440) have announced...
Corxel Pharmaceuticals Secures Global Rights to CX11, a Novel Oral GLP-1 RA, in Licensing Deal with Vincentage
China-based Corxel Pharmaceuticals (CORXEL) has announced a significant licensing agreement with domestic firm Vincentage, securing...
ETERN Therapeutics’ YAP/TEAD Inhibitor ETS-006 Wins FDA Clinical Approval for Advanced Solid Tumors
China-based biopharmaceutical company ETERN Therapeutics has announced that it has received clinical approval from the...
Bristol-Myers Squibb’s Opdivo-Yervoy Combo Approved by EC for MSI-H/mCRC
Global biopharmaceutical company Bristol-Myers Squibb (BMS, NYSE: BMY) has announced that it has received marketing...
Roche’s Lunsumio Receives NMPA Approval for R/R Follicular Lymphoma Treatment
Swiss pharmaceutical giant Roche (SWX: ROG) has announced that it has received marketing approval from...
BeiGene Rebrands to BeOne Medicines Ltd, Ticker Symbol Changes to “ONC”
China-based BeiGene Ltd, listed on Nasdaq (NASDAQ: BGNE, HKG: 6160, SHA: 688235), has announced a...
RAPT Therapeutics Secures Ex-China Rights to Jemincare Group’s Anti-IgE Antibody JYB1904
US-based biopharmaceutical company RAPT Therapeutics Inc. (NASDAQ: RAPT) has announced that it has obtained the...